Experimental Immune-Boosting drug now available for bone cancer patients

NCT ID NCT04571229

AVAILABLE Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers L-MTP-PE, an investigational drug that activates white blood cells to fight cancer, to people with osteosarcoma. Eligible patients include those with newly diagnosed or relapsed osteosarcoma who have had surgery to remove all detectable cancer. The drug is given as an infusion over 36 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L-MTP-PE (a drug that activates white blood cells to help the immune system kill cancer cells)
What this could lead to: If it works, this could provide a treatment option for people with osteosarcoma, especially those who have not responded to standard therapies.
What could go wrong: This is an expanded access program, not a formal trial, so effectiveness is not proven. The drug is still investigational and may not work for everyone. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
AVAILABLE

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.